Current Pharmaceutical Design

Hamann, M.T. (2003) Enhancing marine natural product structural diversity and bioactivity through semisynthesis and biocatalysis. Current Pharmaceutical Design, 9, (11) 879-889. 

Mechoulam R (2000). Looking back at cannabis research. Current Pharmaceutical Design, 6(13), 1313-1322. 

Basser, R. 2002. The impact of thrombopoietin on clinical practice. Current Pharmaceutical Design 8(5), 369-377. 

Salzet, M. 2002. Leech thrombin inhibitors. Current Pharmaceutical Design 8(7), 493-503. 

Singh, M. and O Hagan, D. 2002. Recent advances in vaccine adjuvants. Pharmaceutical Research 19(6), 715-728. Spearman, P. 2006. Current progress in the development of HIV vaccines. Current Pharmaceutical Design 12(9), 1147-1167. 

Stevceva, L. and Ferrari, M 2005. Mucosal adjuvants. Current Pharmaceutical Design 11(6), 801-811. 

Schuster, D., Laggner, C. and Langer, T. (2005) Why drugs fail - a study on side effects in new chemical entities. Current Pharmaceutical Design, 11, 3545-3559. 

New methodologies for ligand-based virtual screening. Current Pharmaceutical Design, 11, 1189-1192. 

Inhibitors of NAD -I- dependent histone deacetylases (sirtuins). Current Pharmaceutical Design, 14, 562-573. 

Pessina, A., Malerba, 1. and Gribaldo, L. (2005) Hematotoxicity testing by cell clonogenic assay in drug development and preclinical trials. Current Pharmaceutical Design, 11, 1055-1065. 

Zartler, E. R., and Shapiro, M. J. (2006). Protein NMR-based screening in drug discovery. Current Pharmaceutical Design 12, 3963-3972. 

Neutra M.R., Phillips T.L. and Phillips T.E. (1984). Regulation of intestinal goblet cells in situ, in mucosal explants and in the isolated epithelium. Ciba Found. Symp. 109, 20-39 Nguyen T., Chin W-C. and Verdugo P. (1998). Role of Ca2 + /K+ ion exchange in intracellular storage and release of Ca2+. Nature 395, 908-912 Nochi T. and Kiyono H. (2006) Innate immunity in the mucosal immune system. Current Pharmaceutical Design 12,4203 1213... 

Singh, M. (1999) Transferrin as a targeting ligand for liposomes and anticancer drags. Current Pharmaceutical Design 5 443-451. 

Mori, T. (2004) Cancer-specific ligands identified from screening of peptide-display libraries. Current Pharmaceutical Design 10 2335-2343. 

Krogsgaard-Larsen, P., Eroelund, B. and Erydenvang, K. (2000) Current Pharmaceutical Design, 6,1193-1209. 

Thomas SA (2004) Anti-HIV drug distribution to the central nervous system. Current Pharmaceutical Design 10 1313—1324. 

Medina, O.P. Zhu, Y. Kairemo, K. Targeted liposomal drug dehvery in cancer. Current Pharmaceutical Design 2004, 10, 2981-2989. 

Bergamini CM, Gambetti S, Dond A, and Cervellat C (2004) Oxygen, reactive oxygen species and tissue damage. Current Pharmaceutical Design 10 1611-1626. 

Nuti, E., Tuccinardi, T. and Rossello, A. (2007) Matrix metalloproteinase inhibitors new challenges in the era of post broad-spectrum inhibitors. Current Pharmaceutical Design, 13, 2087-2100. 

Wang, W., Jiang, J., Ballard, C.E. and Wang, B. (1999) Prodrug approaches in the improved delivery of peptide drugs. Current Pharmaceutical Design, 5,... 

Begley, D. (2004) ABC transporters and the blood-brain barrier. Current Pharmaceutical Design, 10, 1295-1312. 

Roepe, P.D. (2000) What is the precise role ofhuman MDR 1 protein in chemotherapeutic drug resistance Current Pharmaceutical Design, 6 (3), 241-260. 

Bentham Scientific Publishers Current Pharmaceutical Design http //www.bentham. org/cpd/... 

Steinmeyer, A. et al. (2000) New synthetic vitamin D analogs with antiproliferative activities. Current Pharmaceutical Design, 6, 767-789. 

Youngster, S., Wang, Yu-Sen, Grace, M., Bausch, 1., Bordens, R., Wyss, D. F. Structure, biology and therapeutic implications of PEGylated interferon Alpha-2b. Current Pharmaceutical Design 2002 8 2139-2157. 

Grasshoff, C., Drexler, B., et al. (2006). Anaesthetic drugs Linking molecular actions to clinical effects. Current Pharmaceutical Design, 72(28), 3665-3679. 

Leviton, I. (2003). Separating fact from fiction The data behind allergies and side effects caused by penicillins, cephalosporins, and carbapenem antibiotics. Current Pharmaceutical Design, 9 (12), 983-988. 

---